Recon: AbbVie wins FDA approval for 24-hour Parkinson’s infusion treatment; FDA expands use of Avadel’s narcolepsy drug to children 7 and older
ReconJason Scott
Approval/marketing authorizationBiologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)